For example, the gradual discovery of immune checkpoints such as PD-1, PD-L1, CTLA-4, and OX40 has led to the emergence of immune checkpoint inhibitors for CRC therapy (67). This evidence concerns the gene TNFRSF4 and colorectal carcinoma.